Not applicableUnknownNCT05996263
What this trial is testing
Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)
Who this might be right for
Lung Cancer Stage IIILung Cancer Stage IV
University Hospital, Brest 75